AdverseEvent.ai
This page presents data from the FDA Adverse Event Reporting System (FAERS) and the FDA-approved drug label. A report submitted to FAERS does not prove a drug caused the reported event. Always consult a healthcare provider about medications.

Epinephrine

catecholamine
Last updated: September 2, 2026
Preview tracking

Epinephrine is a medication, a catecholamine. According to the FDA-approved label, Epinephrine is a non-selective alpha and beta adrenergic agonist indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. ( 1.1 ) 1.1 Hypotension associated with Septic Shock Epinephrine Injection USP, 1 mg/10 mL. FAERS contains 65,096 submissions naming this drug from 1999 through 2026; the top three reactions cited are drug ineffective, headache, and sinusitis.

Most-Reported Reactions

Counts of the reactions most often cited in FAERS submissions that named Epinephrine. Inclusion here does not establish causation - submitters describe what was observed, not what was confirmed. One submission can list several reactions, so the totals exceed the report count.

DRUG INEFFECTIVE 5,928 (9.1%) HEADACHE 4,393 (6.7%) SINUSITIS 4,030 (6.2%) FATIGUE 4,007 (6.2%) DYSPNOEA 3,449 (5.3%) NAUSEA 3,352 (5.1%) PAIN 3,337 (5.1%) PRODUCT DOSE OMISSION ISSUE 3,223 (5.0%) OFF LABEL USE 2,916 (4.5%) PNEUMONIA 2,644 (4.1%) COVID-19 2,629 (4.0%) COUGH 2,261 (3.5%) PYREXIA 2,216 (3.4%) NASOPHARYNGITIS 2,191 (3.4%) RASH 2,145 (3.3%)

Patient Demographics

Patient sex and age across the FAERS submissions that named Epinephrine. Percentages here are computed only from submissions where these fields were filled in - many leave them blank.

By Sex

Female Male Unknown

By Age Group

0-17 18-44 45-64 65+

Severity Outcomes

Severity flags recorded across the 65,096 FAERS submissions that named Epinephrine. Each bar shows the count of those reports carrying that flag. A single case can carry more than one (a hospitalization that became life-threatening, for example), so these bars are independent rates - they don't sum to 100%. Inclusion of a case under any flag does not establish that the drug caused the outcome.

DEATH 4,074 (6.3%) HOSPITALIZATION 17,874 (27.5%) LIFE-THREATENING 5,077 (7.8%) DISABLING 677 (1.0%)

Submissions Per Quarter

Quarterly count of FAERS submissions that named Epinephrine. Ups and downs on this chart can track prescribing volume, news cycles, or shifts in how reports get filed, rather than the drug becoming safer or more dangerous.

1999 2002 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026

From the FDA-Approved Label

Excerpts from the official FDA-approved prescribing information for Epinephrine. This is the authoritative source on indications, warnings, and known adverse reactions.

Indications

1 INDICATIONS AND USAGE Epinephrine is a non-selective alpha and beta adrenergic agonist indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. ( 1.1 ) 1.1 Hypotension associated with Septic Shock Epinephrine Injection USP, 1 mg/10 mL (0.1 mg/mL) is indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock.

Adverse Reactions (from label)

6 ADVERSE REACTIONS The following adverse reactions are discussed elsewhere in labeling: • Hypertension [see Warnings and Precautions (5.1)] • Pulmonary Edema [see Warnings and Precautions (5.2)] • Cardiac Arrhythmias and Ischemia [see Warnings and Precautions (5.3)] • Extravassation and Tissue Necrosis with Intravenous Infusion [see Warnings and Precautions (5.4)] • Renal Impairment [see Warnings and Precautions (5.5)] • Allergic Reactions associated with Sulfite [see Warnings and Precautions (5.6)] The following adverse reactions associated with the infusion of epinephrine were identified in the literature. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or to establish a causal relationship to drug exposure. Cardiovascular disorders: tachycardia, supraventricular tachycardia, ventricular arrhythmias, myocardial ischemia, myocardial infarction, limb ischemia, pulmonary edema Gastrointestinal disorders : Nausea, vomiting General disorders and administrative site conditions : Chest pain, extravasation Metabolic : hypoglycemia, hyperglycemia, insulin resistance, hypokalemia, lactic a...

FDA label effective date: 2026-06-08

Disclaimer

AdverseEvent.ai is not affiliated with the FDA. Adverse-event counts come from the FDA Adverse Event Reporting System (FAERS). Drug labels come from the FDA drug label dataset. A report submitted to FAERS does not prove a drug caused the reported event — always consult a healthcare provider about medications. This site is for informational purposes only and is not medical advice.